
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares explains how type 2 immunity evolved to protect against parasites, venoms, and toxins, and how its dysregulation can result in aberrant type 2 inflammation underlying multiple chronic inflammatory diseases.

Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .

Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

Professor Celeste Porsbjerg presents the pathophysiology and disease processes involved in airway remodeling in severe asthma.
Dr. Sarina Elmariah explains the importance of neuroimmune crosstalk in the development of prurigo nodularis.
Professor Enno Schmidt discusses the pathophysiology of BP, focusing on the role of type 2 inflammation and blister formation
The pathophysiology of chronic spontaneous urticaria (CSU) is complex and involves mast cell degranulation and elements of type 2 inflammation. Learn more about the role of mast cells, basophils, and type 2 inflammatory cells and cytokines involved in the pathophysiology of CSU.
Dr. Butler explores how type 2 inflammation is a common underlying mechanism in several prevalent chronic pruritic skin conditions affecting the elderly, such as CPUO, AD, BP, and PN

Dr. Jason Hawkes details the role of IL-4 and IL-13 in the pathophysiology of CSU at EADV 2025

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.